| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 38 | 2019 | 1428 | 3.210 |
Why?
|
| Prostatic Neoplasms | 28 | 2016 | 492 | 2.430 |
Why?
|
| Genetic Predisposition to Disease | 37 | 2018 | 849 | 2.390 |
Why?
|
| Polymorphism, Single Nucleotide | 43 | 2018 | 1092 | 2.320 |
Why?
|
| Cognition Disorders | 15 | 2018 | 383 | 1.860 |
Why?
|
| Exercise | 19 | 2019 | 655 | 1.440 |
Why?
|
| Male | 142 | 2021 | 19488 | 1.440 |
Why?
|
| Aged | 97 | 2021 | 10398 | 1.340 |
Why?
|
| Genome-Wide Association Study | 26 | 2019 | 560 | 1.250 |
Why?
|
| European Continental Ancestry Group | 22 | 2019 | 1180 | 1.250 |
Why?
|
| Humans | 160 | 2021 | 32297 | 1.240 |
Why?
|
| Brain | 12 | 2018 | 971 | 1.240 |
Why?
|
| Female | 116 | 2021 | 20126 | 1.210 |
Why?
|
| African Americans | 15 | 2019 | 1443 | 1.150 |
Why?
|
| Cardiovascular Diseases | 17 | 2018 | 1133 | 1.140 |
Why?
|
| Mobility Limitation | 13 | 2019 | 221 | 1.140 |
Why?
|
| Linkage Disequilibrium | 9 | 2019 | 192 | 1.120 |
Why?
|
| Middle Aged | 77 | 2020 | 11949 | 1.060 |
Why?
|
| Chromosome Mapping | 8 | 2013 | 193 | 1.000 |
Why?
|
| Body Mass Index | 12 | 2019 | 921 | 0.960 |
Why?
|
| Risk Factors | 47 | 2020 | 3876 | 0.960 |
Why?
|
| Aged, 80 and over | 51 | 2019 | 4050 | 0.950 |
Why?
|
| Geriatric Assessment | 14 | 2018 | 395 | 0.920 |
Why?
|
| Inflammation | 9 | 2019 | 542 | 0.770 |
Why?
|
| Organ Size | 5 | 2018 | 220 | 0.770 |
Why?
|
| Adiposity | 7 | 2016 | 197 | 0.770 |
Why?
|
| Disability Evaluation | 7 | 2018 | 236 | 0.750 |
Why?
|
| Stroke | 8 | 2018 | 585 | 0.750 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2020 | 1345 | 0.710 |
Why?
|
| Genetic Loci | 8 | 2019 | 149 | 0.710 |
Why?
|
| Hippocampus | 3 | 2016 | 173 | 0.680 |
Why?
|
| Life Style | 12 | 2019 | 404 | 0.670 |
Why?
|
| Software | 3 | 2015 | 126 | 0.660 |
Why?
|
| Atherosclerosis | 14 | 2018 | 770 | 0.660 |
Why?
|
| Body Composition | 5 | 2015 | 384 | 0.660 |
Why?
|
| Cognition | 8 | 2018 | 551 | 0.660 |
Why?
|
| Coronary Artery Disease | 9 | 2018 | 397 | 0.620 |
Why?
|
| Blood Pressure | 7 | 2018 | 859 | 0.620 |
Why?
|
| Health Education | 8 | 2018 | 157 | 0.610 |
Why?
|
| Frail Elderly | 5 | 2018 | 70 | 0.600 |
Why?
|
| Homocysteine | 4 | 2015 | 15 | 0.590 |
Why?
|
| Pedigree | 7 | 2018 | 141 | 0.560 |
Why?
|
| Adult | 37 | 2021 | 9467 | 0.550 |
Why?
|
| Epistasis, Genetic | 5 | 2018 | 44 | 0.540 |
Why?
|
| Anxiety | 5 | 2020 | 185 | 0.530 |
Why?
|
| Aging | 5 | 2019 | 953 | 0.530 |
Why?
|
| Cohort Studies | 19 | 2020 | 1832 | 0.520 |
Why?
|
| Models, Genetic | 12 | 2018 | 94 | 0.510 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2014 | 146 | 0.510 |
Why?
|
| Quality of Life | 5 | 2020 | 915 | 0.500 |
Why?
|
| Vascular Diseases | 1 | 2015 | 66 | 0.500 |
Why?
|
| Case-Control Studies | 18 | 2015 | 911 | 0.490 |
Why?
|
| United States | 24 | 2018 | 3983 | 0.480 |
Why?
|
| Obesity | 8 | 2019 | 1164 | 0.470 |
Why?
|
| Exercise Therapy | 5 | 2021 | 259 | 0.470 |
Why?
|
| Quantitative Trait, Heritable | 5 | 2015 | 47 | 0.460 |
Why?
|
| Breast Neoplasms | 5 | 2020 | 759 | 0.460 |
Why?
|
| Lipids | 3 | 2019 | 226 | 0.450 |
Why?
|
| Genetic Variation | 9 | 2018 | 247 | 0.450 |
Why?
|
| Computational Biology | 3 | 2018 | 90 | 0.440 |
Why?
|
| Genotype | 17 | 2019 | 742 | 0.440 |
Why?
|
| Cranial Irradiation | 5 | 2013 | 93 | 0.440 |
Why?
|
| Insulin Resistance | 6 | 2018 | 460 | 0.430 |
Why?
|
| Genetic Association Studies | 6 | 2016 | 147 | 0.420 |
Why?
|
| Motor Activity | 5 | 2019 | 327 | 0.420 |
Why?
|
| Genetic Markers | 8 | 2013 | 125 | 0.410 |
Why?
|
| Transcobalamins | 1 | 2011 | 4 | 0.400 |
Why?
|
| Adipose Tissue | 5 | 2016 | 345 | 0.400 |
Why?
|
| Body Weight | 6 | 2019 | 311 | 0.380 |
Why?
|
| Hispanic Americans | 6 | 2019 | 949 | 0.380 |
Why?
|
| Models, Theoretical | 1 | 2012 | 138 | 0.380 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 23 | 0.360 |
Why?
|
| Risk Assessment | 16 | 2018 | 1447 | 0.350 |
Why?
|
| Dog Diseases | 2 | 2020 | 8 | 0.350 |
Why?
|
| Walking | 8 | 2017 | 204 | 0.350 |
Why?
|
| Brain Ischemia | 3 | 2017 | 146 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2009 | 13 | 0.340 |
Why?
|
| ROC Curve | 6 | 2018 | 171 | 0.340 |
Why?
|
| Models, Statistical | 4 | 2017 | 176 | 0.340 |
Why?
|
| C-Reactive Protein | 5 | 2015 | 238 | 0.330 |
Why?
|
| Albuminuria | 4 | 2017 | 181 | 0.330 |
Why?
|
| DNA, Mitochondrial | 2 | 2018 | 34 | 0.320 |
Why?
|
| Cross-Sectional Studies | 14 | 2020 | 1522 | 0.320 |
Why?
|
| Continental Population Groups | 3 | 2019 | 239 | 0.320 |
Why?
|
| Depression | 3 | 2020 | 436 | 0.320 |
Why?
|
| Hypertension | 6 | 2018 | 972 | 0.310 |
Why?
|
| Polymorphism, Genetic | 5 | 2014 | 194 | 0.310 |
Why?
|
| Pericardium | 4 | 2013 | 54 | 0.300 |
Why?
|
| Phenotype | 10 | 2019 | 656 | 0.300 |
Why?
|
| Smoking | 3 | 2019 | 493 | 0.290 |
Why?
|
| Quantitative Trait Loci | 6 | 2018 | 143 | 0.290 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2017 | 33 | 0.290 |
Why?
|
| Microglia | 4 | 2013 | 58 | 0.290 |
Why?
|
| Lower Extremity | 3 | 2017 | 101 | 0.290 |
Why?
|
| Absorptiometry, Photon | 2 | 2017 | 133 | 0.280 |
Why?
|
| PPAR alpha | 3 | 2014 | 29 | 0.280 |
Why?
|
| Gene Frequency | 7 | 2017 | 221 | 0.280 |
Why?
|
| Logistic Models | 7 | 2013 | 788 | 0.270 |
Why?
|
| Adolescent | 14 | 2019 | 3571 | 0.270 |
Why?
|
| Pilot Projects | 8 | 2021 | 536 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2017 | 920 | 0.270 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 257 | 0.270 |
Why?
|
| Algorithms | 7 | 2015 | 497 | 0.260 |
Why?
|
| Computer Simulation | 5 | 2016 | 220 | 0.260 |
Why?
|
| Accidents, Traffic | 2 | 2018 | 195 | 0.250 |
Why?
|
| Neuropsychological Tests | 5 | 2018 | 379 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 6 | 2009 | 64 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2009 | 14 | 0.240 |
Why?
|
| Coronary Vessels | 4 | 2018 | 158 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2008 | 13 | 0.240 |
Why?
|
| Regression Analysis | 5 | 2015 | 296 | 0.220 |
Why?
|
| Postoperative Complications | 3 | 2018 | 788 | 0.220 |
Why?
|
| PPAR delta | 2 | 2013 | 3 | 0.220 |
Why?
|
| Calcinosis | 4 | 2013 | 145 | 0.210 |
Why?
|
| Personality Disorders | 3 | 2007 | 5 | 0.210 |
Why?
|
| Proportional Hazards Models | 8 | 2018 | 759 | 0.210 |
Why?
|
| Family Health | 5 | 2012 | 77 | 0.210 |
Why?
|
| Animals | 15 | 2020 | 7694 | 0.210 |
Why?
|
| Dementia | 2 | 2015 | 256 | 0.210 |
Why?
|
| Ultrasonography | 4 | 2020 | 398 | 0.210 |
Why?
|
| Waist Circumference | 4 | 2016 | 91 | 0.210 |
Why?
|
| Bone Density | 2 | 2017 | 186 | 0.200 |
Why?
|
| Survival Analysis | 3 | 2020 | 491 | 0.200 |
Why?
|
| Neurogenesis | 2 | 2013 | 16 | 0.200 |
Why?
|
| Diet | 2 | 2020 | 384 | 0.200 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 779 | 0.200 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2012 | 141 | 0.200 |
Why?
|
| Hand Strength | 3 | 2017 | 100 | 0.200 |
Why?
|
| Diabetic Angiopathies | 4 | 2015 | 144 | 0.190 |
Why?
|
| Linear Models | 7 | 2020 | 454 | 0.190 |
Why?
|
| Glioma | 2 | 2020 | 136 | 0.190 |
Why?
|
| Ethnic Groups | 4 | 2013 | 480 | 0.190 |
Why?
|
| Single-Blind Method | 7 | 2018 | 200 | 0.190 |
Why?
|
| Family | 5 | 2018 | 115 | 0.190 |
Why?
|
| Glutaminase | 1 | 2020 | 2 | 0.190 |
Why?
|
| Cholesterol, HDL | 3 | 2019 | 176 | 0.190 |
Why?
|
| INDEL Mutation | 2 | 2018 | 11 | 0.190 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 11 | 0.190 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2020 | 18 | 0.190 |
Why?
|
| Transcription Factor AP-1 | 2 | 2012 | 19 | 0.190 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2012 | 34 | 0.190 |
Why?
|
| Gait | 4 | 2014 | 130 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 29 | 0.180 |
Why?
|
| Urea | 1 | 2020 | 39 | 0.180 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 2296 | 0.180 |
Why?
|
| Muscle Strength | 2 | 2018 | 157 | 0.180 |
Why?
|
| Thiophenes | 1 | 2020 | 24 | 0.180 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 7 | 0.180 |
Why?
|
| Activities of Daily Living | 3 | 2017 | 258 | 0.180 |
Why?
|
| Intracranial Pressure | 1 | 2020 | 20 | 0.180 |
Why?
|
| Osteoarthritis, Knee | 1 | 2021 | 89 | 0.180 |
Why?
|
| Acids | 1 | 2020 | 3 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 38 | 0.180 |
Why?
|
| Self Disclosure | 1 | 2020 | 23 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 877 | 0.180 |
Why?
|
| Intracranial Hypertension | 1 | 2020 | 21 | 0.180 |
Why?
|
| Mexican Americans | 2 | 2018 | 60 | 0.180 |
Why?
|
| NF-kappa B | 2 | 2012 | 82 | 0.180 |
Why?
|
| Receptors, Opioid, mu | 1 | 2020 | 55 | 0.180 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.180 |
Why?
|
| Pruritus | 1 | 2020 | 64 | 0.180 |
Why?
|
| Gastroparesis | 1 | 2019 | 11 | 0.180 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 105 | 0.180 |
Why?
|
| Taxoids | 1 | 2020 | 59 | 0.180 |
Why?
|
| Diabetes Complications | 3 | 2018 | 180 | 0.180 |
Why?
|
| Interleukin-6 | 3 | 2012 | 248 | 0.180 |
Why?
|
| Anxiety Disorders | 2 | 2010 | 77 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 89 | 0.170 |
Why?
|
| Median Nerve | 1 | 2020 | 51 | 0.170 |
Why?
|
| Fatty Liver | 2 | 2011 | 67 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 95 | 0.170 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 51 | 0.170 |
Why?
|
| North Carolina | 6 | 2019 | 1520 | 0.170 |
Why?
|
| Stereotaxic Techniques | 1 | 2019 | 23 | 0.170 |
Why?
|
| Analgesics | 1 | 2020 | 127 | 0.170 |
Why?
|
| Blood Glucose | 3 | 2018 | 496 | 0.170 |
Why?
|
| Alleles | 4 | 2013 | 252 | 0.170 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2019 | 1 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 3 | 2017 | 309 | 0.170 |
Why?
|
| Respiratory Muscles | 1 | 2018 | 7 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2018 | 511 | 0.170 |
Why?
|
| Alzheimer Disease | 2 | 2013 | 351 | 0.170 |
Why?
|
| Transients and Migrants | 2 | 2019 | 293 | 0.160 |
Why?
|
| Meningioma | 1 | 2019 | 57 | 0.160 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2007 | 27 | 0.160 |
Why?
|
| Longitudinal Studies | 6 | 2019 | 786 | 0.160 |
Why?
|
| Factor Analysis, Statistical | 4 | 2012 | 75 | 0.160 |
Why?
|
| African Continental Ancestry Group | 6 | 2019 | 364 | 0.160 |
Why?
|
| Mentors | 1 | 2018 | 31 | 0.160 |
Why?
|
| Prognosis | 7 | 2019 | 1523 | 0.160 |
Why?
|
| Metabolome | 1 | 2018 | 36 | 0.160 |
Why?
|
| Subcutaneous Fat | 2 | 2016 | 46 | 0.160 |
Why?
|
| Enzyme Activation | 2 | 2020 | 135 | 0.150 |
Why?
|
| Radius | 1 | 2017 | 26 | 0.150 |
Why?
|
| Mitochondrial Proteins | 1 | 2018 | 67 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2019 | 122 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 35 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2018 | 186 | 0.150 |
Why?
|
| von Willebrand Factor | 1 | 2017 | 16 | 0.150 |
Why?
|
| Hypoglycemic Agents | 2 | 2016 | 188 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 112 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2018 | 78 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2015 | 99 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 370 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 65 | 0.140 |
Why?
|
| Glucose | 1 | 2018 | 177 | 0.140 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2017 | 23 | 0.140 |
Why?
|
| Odds Ratio | 4 | 2014 | 480 | 0.140 |
Why?
|
| Medical History Taking | 2 | 2016 | 37 | 0.140 |
Why?
|
| Disabled Persons | 1 | 2017 | 103 | 0.140 |
Why?
|
| Mortality | 1 | 2017 | 126 | 0.140 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2009 | 45 | 0.140 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2008 | 41 | 0.140 |
Why?
|
| Asian Continental Ancestry Group | 5 | 2019 | 111 | 0.140 |
Why?
|
| Insulin | 3 | 2015 | 368 | 0.140 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 638 | 0.140 |
Why?
|
| Artificial Intelligence | 2 | 2013 | 55 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2018 | 167 | 0.140 |
Why?
|
| Mechanical Phenomena | 1 | 2016 | 28 | 0.140 |
Why?
|
| Women's Health | 1 | 2018 | 235 | 0.140 |
Why?
|
| Apolipoproteins E | 1 | 2016 | 99 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2016 | 110 | 0.140 |
Why?
|
| Janus Kinase 1 | 1 | 2016 | 5 | 0.140 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2016 | 6 | 0.140 |
Why?
|
| Seasons | 1 | 2016 | 86 | 0.140 |
Why?
|
| Risk | 5 | 2017 | 325 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 262 | 0.130 |
Why?
|
| Area Under Curve | 3 | 2012 | 95 | 0.130 |
Why?
|
| Vitamin K | 1 | 2015 | 9 | 0.130 |
Why?
|
| Toll-Like Receptors | 2 | 2006 | 24 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 926 | 0.130 |
Why?
|
| Occupational Diseases | 1 | 2016 | 81 | 0.130 |
Why?
|
| Preventive Health Services | 1 | 2016 | 44 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 353 | 0.130 |
Why?
|
| Hospitalization | 1 | 2018 | 465 | 0.130 |
Why?
|
| Observer Variation | 1 | 2015 | 109 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 142 | 0.130 |
Why?
|
| Multigene Family | 2 | 2013 | 51 | 0.130 |
Why?
|
| DNA Methylation | 1 | 2016 | 142 | 0.130 |
Why?
|
| Spectrin | 1 | 2014 | 5 | 0.130 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2014 | 12 | 0.130 |
Why?
|
| Young Adult | 5 | 2019 | 2626 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 267 | 0.130 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2014 | 55 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 611 | 0.120 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 23 | 0.120 |
Why?
|
| Abdominal Fat | 2 | 2012 | 48 | 0.120 |
Why?
|
| Methionine | 1 | 2014 | 8 | 0.120 |
Why?
|
| R-SNARE Proteins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Syntaxin 1 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2014 | 7 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 293 | 0.120 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2014 | 36 | 0.120 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 126 | 0.120 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2014 | 41 | 0.120 |
Why?
|
| Mutation | 2 | 2018 | 503 | 0.120 |
Why?
|
| Genome, Human | 2 | 2017 | 133 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3514 | 0.110 |
Why?
|
| Prevalence | 5 | 2019 | 986 | 0.110 |
Why?
|
| Haplotypes | 3 | 2008 | 224 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 5 | 0.110 |
Why?
|
| Bilirubin | 1 | 2013 | 23 | 0.110 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 11 | 0.110 |
Why?
|
| Thiazoles | 1 | 2013 | 32 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 1 | 2013 | 18 | 0.110 |
Why?
|
| Genetics, Population | 1 | 2013 | 32 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2014 | 184 | 0.110 |
Why?
|
| Uric Acid | 1 | 2013 | 24 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2012 | 19 | 0.110 |
Why?
|
| Cell Survival | 3 | 2020 | 301 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 362 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2014 | 187 | 0.110 |
Why?
|
| Ramipril | 1 | 2012 | 4 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 675 | 0.100 |
Why?
|
| Time Factors | 4 | 2018 | 2181 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2012 | 99 | 0.100 |
Why?
|
| Sweden | 5 | 2010 | 14 | 0.100 |
Why?
|
| Neoplasms | 1 | 2019 | 695 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2012 | 27 | 0.100 |
Why?
|
| Quality Control | 1 | 2012 | 43 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 262 | 0.100 |
Why?
|
| Heart Ventricles | 1 | 2013 | 137 | 0.100 |
Why?
|
| Physical Fitness | 1 | 2012 | 127 | 0.100 |
Why?
|
| Prostate | 1 | 2012 | 74 | 0.100 |
Why?
|
| Adipose Tissue, White | 1 | 2011 | 6 | 0.100 |
Why?
|
| Genes | 1 | 2011 | 15 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2012 | 78 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 103 | 0.100 |
Why?
|
| Environment | 1 | 2011 | 52 | 0.100 |
Why?
|
| Sex Characteristics | 3 | 2011 | 176 | 0.100 |
Why?
|
| Sex Factors | 4 | 2017 | 674 | 0.100 |
Why?
|
| Systole | 2 | 2018 | 100 | 0.100 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 137 | 0.100 |
Why?
|
| Tumor Necrosis Factors | 1 | 2010 | 4 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 213 | 0.100 |
Why?
|
| Interleukins | 1 | 2010 | 17 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 49 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 514 | 0.090 |
Why?
|
| Pennsylvania | 1 | 2010 | 84 | 0.090 |
Why?
|
| Butyrylcholinesterase | 1 | 2010 | 16 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2020 | 2274 | 0.090 |
Why?
|
| Organophosphorus Compounds | 1 | 2010 | 33 | 0.090 |
Why?
|
| Adiponectin | 1 | 2010 | 104 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2020 | 234 | 0.090 |
Why?
|
| Kidney | 2 | 2020 | 529 | 0.090 |
Why?
|
| Tunica Media | 1 | 2010 | 29 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2013 | 339 | 0.090 |
Why?
|
| Ideal Body Weight | 1 | 2009 | 7 | 0.090 |
Why?
|
| Tunica Intima | 1 | 2010 | 58 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 502 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 39 | 0.090 |
Why?
|
| Mice, Nude | 2 | 2020 | 298 | 0.090 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 33 | 0.090 |
Why?
|
| Dogs | 2 | 2020 | 129 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 25 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 54 | 0.090 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3358 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2009 | 9 | 0.080 |
Why?
|
| Analysis of Variance | 4 | 2012 | 470 | 0.080 |
Why?
|
| Physical Chromosome Mapping | 1 | 2009 | 8 | 0.080 |
Why?
|
| Health | 1 | 2009 | 14 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2009 | 33 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2009 | 20 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 102 | 0.080 |
Why?
|
| Butyrates | 1 | 2008 | 3 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 10 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2008 | 2 | 0.080 |
Why?
|
| Asthma | 2 | 2003 | 438 | 0.080 |
Why?
|
| Tetrazoles | 1 | 2008 | 64 | 0.080 |
Why?
|
| Patient Selection | 2 | 2007 | 289 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 68 | 0.080 |
Why?
|
| Coronary Stenosis | 1 | 2008 | 30 | 0.080 |
Why?
|
| Imidazoles | 1 | 2008 | 97 | 0.080 |
Why?
|
| Macaca mulatta | 2 | 2020 | 332 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.080 |
Why?
|
| Agriculture | 1 | 2010 | 186 | 0.080 |
Why?
|
| Mice | 5 | 2013 | 2524 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 172 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 736 | 0.080 |
Why?
|
| Triglycerides | 2 | 2019 | 230 | 0.080 |
Why?
|
| Liver | 1 | 2011 | 486 | 0.080 |
Why?
|
| Intra-Abdominal Fat | 1 | 2008 | 66 | 0.080 |
Why?
|
| Multifactorial Inheritance | 1 | 2008 | 21 | 0.080 |
Why?
|
| Coronary Disease | 1 | 2009 | 215 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 469 | 0.080 |
Why?
|
| Community-Based Participatory Research | 2 | 2019 | 113 | 0.080 |
Why?
|
| Models, Psychological | 1 | 2007 | 24 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 696 | 0.080 |
Why?
|
| Pesticides | 1 | 2010 | 202 | 0.080 |
Why?
|
| Hemorheology | 1 | 2007 | 7 | 0.070 |
Why?
|
| Hyperemia | 1 | 2007 | 10 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2010 | 238 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 68 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2007 | 47 | 0.070 |
Why?
|
| Taiwan | 3 | 2011 | 11 | 0.070 |
Why?
|
| Communication | 2 | 2018 | 140 | 0.070 |
Why?
|
| Vasodilation | 1 | 2007 | 93 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 49 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 128 | 0.070 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2006 | 6 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 124 | 0.070 |
Why?
|
| Rats | 4 | 2014 | 1675 | 0.070 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2006 | 4 | 0.070 |
Why?
|
| Heart | 1 | 2007 | 182 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 106 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 154 | 0.070 |
Why?
|
| Calcium | 1 | 2008 | 310 | 0.070 |
Why?
|
| Radiography | 3 | 2013 | 377 | 0.070 |
Why?
|
| Nuclear Family | 2 | 2003 | 15 | 0.070 |
Why?
|
| Recurrence | 2 | 2017 | 266 | 0.070 |
Why?
|
| Comorbidity | 3 | 2014 | 572 | 0.070 |
Why?
|
| Socialization | 1 | 2005 | 4 | 0.060 |
Why?
|
| Databases, Genetic | 2 | 2018 | 37 | 0.060 |
Why?
|
| Rats, Inbred F344 | 3 | 2012 | 135 | 0.060 |
Why?
|
| Gene Expression | 2 | 2017 | 345 | 0.060 |
Why?
|
| Age Factors | 3 | 2016 | 1204 | 0.060 |
Why?
|
| Biopsy | 2 | 2019 | 273 | 0.060 |
Why?
|
| Social Behavior | 1 | 2005 | 65 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2019 | 65 | 0.060 |
Why?
|
| Survival Rate | 2 | 2017 | 894 | 0.060 |
Why?
|
| Energy Intake | 1 | 2005 | 128 | 0.060 |
Why?
|
| Renal Artery | 1 | 2004 | 48 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2003 | 5 | 0.060 |
Why?
|
| Matched-Pair Analysis | 1 | 2003 | 12 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2003 | 15 | 0.060 |
Why?
|
| Adult Children | 1 | 2003 | 4 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2003 | 15 | 0.060 |
Why?
|
| Siblings | 1 | 2003 | 25 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 122 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2018 | 355 | 0.060 |
Why?
|
| Incidence | 3 | 2017 | 1207 | 0.060 |
Why?
|
| Child | 3 | 2019 | 2472 | 0.060 |
Why?
|
| Registries | 3 | 2010 | 300 | 0.050 |
Why?
|
| Barbados | 1 | 2002 | 1 | 0.050 |
Why?
|
| Immunoglobulin E | 1 | 2002 | 50 | 0.050 |
Why?
|
| Health Behavior | 2 | 2014 | 229 | 0.050 |
Why?
|
| Patient Compliance | 2 | 2016 | 227 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2004 | 255 | 0.050 |
Why?
|
| Europe | 2 | 2014 | 83 | 0.050 |
Why?
|
| Transfection | 2 | 2014 | 202 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2020 | 701 | 0.050 |
Why?
|
| Interleukin-1beta | 2 | 2013 | 42 | 0.050 |
Why?
|
| Phosphoserine | 1 | 2020 | 8 | 0.050 |
Why?
|
| Health Status | 2 | 2017 | 402 | 0.050 |
Why?
|
| Thiadiazoles | 1 | 2020 | 1 | 0.050 |
Why?
|
| Phthalazines | 1 | 2020 | 4 | 0.050 |
Why?
|
| Benzeneacetamides | 1 | 2020 | 4 | 0.050 |
Why?
|
| Glutamine | 1 | 2020 | 9 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2020 | 65 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2012 | 19 | 0.050 |
Why?
|
| Glutathione | 1 | 2020 | 45 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2020 | 55 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2020 | 16 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 171 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 119 | 0.050 |
Why?
|
| Piperazines | 1 | 2020 | 60 | 0.050 |
Why?
|
| China | 1 | 2020 | 50 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2020 | 35 | 0.040 |
Why?
|
| Base Sequence | 2 | 2012 | 257 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 29 | 0.040 |
Why?
|
| Epidermis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 46 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 42 | 0.040 |
Why?
|
| Forearm | 1 | 2020 | 43 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 37 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 67 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 48 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 66 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 190 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2012 | 158 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 5 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 91 | 0.040 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 19 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2014 | 846 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 16 | 0.040 |
Why?
|
| Inhalation | 1 | 2018 | 8 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2019 | 35 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 35 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 23 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 45 | 0.040 |
Why?
|
| Pressure | 1 | 2018 | 54 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2019 | 59 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2019 | 123 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2019 | 95 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 122 | 0.040 |
Why?
|
| Hyperalgesia | 1 | 2019 | 88 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 103 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 28 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 56 | 0.040 |
Why?
|
| Reference Values | 2 | 2010 | 255 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 69 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 41 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2019 | 158 | 0.040 |
Why?
|
| Metabolomics | 1 | 2018 | 53 | 0.040 |
Why?
|
| Femur Neck | 1 | 2017 | 19 | 0.040 |
Why?
|
| Mammaplasty | 1 | 2018 | 28 | 0.040 |
Why?
|
| Diastole | 1 | 2018 | 100 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 422 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2019 | 181 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2017 | 41 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 35 | 0.040 |
Why?
|
| Homeostasis | 1 | 2018 | 133 | 0.040 |
Why?
|
| Mastectomy | 1 | 2018 | 65 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2018 | 148 | 0.040 |
Why?
|
| Papillomavirus Vaccines | 1 | 2018 | 44 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 104 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2019 | 260 | 0.040 |
Why?
|
| Cholesterol | 1 | 2019 | 251 | 0.040 |
Why?
|
| Creatinine | 1 | 2017 | 200 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 98 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 65 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 90 | 0.040 |
Why?
|
| Demography | 1 | 2017 | 109 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2018 | 147 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 222 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 462 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 98 | 0.040 |
Why?
|
| Heterozygote | 1 | 2016 | 57 | 0.040 |
Why?
|
| CpG Islands | 1 | 2016 | 46 | 0.030 |
Why?
|
| Placebos | 1 | 2016 | 66 | 0.030 |
Why?
|
| Acceleration | 1 | 2016 | 63 | 0.030 |
Why?
|
| Probability | 1 | 2016 | 160 | 0.030 |
Why?
|
| Abdominal Injuries | 1 | 2016 | 33 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 454 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2016 | 84 | 0.030 |
Why?
|
| Time | 1 | 2016 | 23 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2009 | 213 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 1076 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2015 | 43 | 0.030 |
Why?
|
| Thoracic Injuries | 1 | 2016 | 51 | 0.030 |
Why?
|
| Biometry | 1 | 2015 | 14 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 171 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 2015 | 26 | 0.030 |
Why?
|
| Resistance Training | 1 | 2016 | 80 | 0.030 |
Why?
|
| Physical Endurance | 1 | 2015 | 35 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 315 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 1281 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 79 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2015 | 46 | 0.030 |
Why?
|
| Quadriceps Muscle | 1 | 2015 | 36 | 0.030 |
Why?
|
| Diaphragm | 1 | 2015 | 46 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 101 | 0.030 |
Why?
|
| Vitamins | 1 | 2015 | 68 | 0.030 |
Why?
|
| Health Promotion | 2 | 2007 | 242 | 0.030 |
Why?
|
| Memory | 1 | 2016 | 191 | 0.030 |
Why?
|
| Critical Illness | 1 | 2015 | 89 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 118 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 36 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Carbon | 1 | 2014 | 12 | 0.030 |
Why?
|
| Folic Acid | 1 | 2014 | 13 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2014 | 49 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 167 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 316 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 177 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2014 | 73 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 244 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 196 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 35 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2013 | 18 | 0.030 |
Why?
|
| Ribosomes | 1 | 2012 | 10 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 225 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 68 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 45 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 22 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2012 | 55 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 10 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 18 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 77 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 98 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 34 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2014 | 262 | 0.030 |
Why?
|
| Calibration | 1 | 2012 | 27 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2011 | 9 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 28 | 0.020 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 25 | 0.020 |
Why?
|
| RNA | 1 | 2012 | 95 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 305 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 74 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 20 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 43 | 0.020 |
Why?
|
| Culture | 1 | 2010 | 41 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2012 | 219 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 89 | 0.020 |
Why?
|
| Heart Rate | 1 | 2012 | 337 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 773 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 302 | 0.020 |
Why?
|
| Urban Population | 1 | 2010 | 87 | 0.020 |
Why?
|
| Angiotensin I | 1 | 2012 | 250 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 137 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 7 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 2009 | 5 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 28 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 313 | 0.020 |
Why?
|
| Cytokines | 1 | 2010 | 262 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 196 | 0.020 |
Why?
|
| Androgens | 1 | 2009 | 34 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 397 | 0.020 |
Why?
|
| Rural Population | 1 | 2010 | 274 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 14 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 50 | 0.020 |
Why?
|
| Luciferases | 1 | 2008 | 33 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 43 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 75 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2008 | 25 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 46 | 0.020 |
Why?
|
| Maryland | 1 | 2008 | 28 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 359 | 0.020 |
Why?
|
| Glucose Intolerance | 1 | 2008 | 47 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 449 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2008 | 100 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2013 | 635 | 0.020 |
Why?
|
| Genes, myc | 1 | 2007 | 5 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 2007 | 28 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2007 | 18 | 0.020 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Selection Bias | 1 | 2007 | 14 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 201 | 0.020 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 24 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2007 | 19 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 143 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2008 | 112 | 0.020 |
Why?
|
| Tourniquets | 1 | 2007 | 11 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2008 | 123 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 600 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2009 | 602 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 92 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 89 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 202 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2007 | 81 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 534 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 320 | 0.020 |
Why?
|
| Skin | 1 | 2008 | 217 | 0.020 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Toll-Like Receptor 10 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 220 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 72 | 0.020 |
Why?
|
| Estrogens | 1 | 2007 | 174 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 279 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 459 | 0.020 |
Why?
|
| Baltimore | 1 | 2006 | 51 | 0.020 |
Why?
|
| Age Distribution | 1 | 2006 | 210 | 0.020 |
Why?
|
| Postmenopause | 1 | 2007 | 409 | 0.020 |
Why?
|
| Solubility | 1 | 2004 | 38 | 0.020 |
Why?
|
| Serum | 1 | 2004 | 20 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 136 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 25 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2003 | 14 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 28 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 90 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 126 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2005 | 190 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2004 | 65 | 0.010 |
Why?
|
| Lod Score | 1 | 2003 | 72 | 0.010 |
Why?
|